Publicaciones en colaboración con investigadores/as de Novartis (Sweden) (17)

2023

  1. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600 Mutant Pediatric High-Grade Glioma

    Journal of Clinical Oncology, Vol. 41, Núm. 33, pp. 5174-5183

  2. Unveiling chronic spontaneous urticaria pathophysiology through systems biology

    Journal of Allergy and Clinical Immunology, Vol. 151, Núm. 4, pp. 1005-1014

2022

  1. EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)

    Future oncology (London, England), Vol. 18, Núm. 31, pp. 3481-3492

2021

  1. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study

    Arthritis and Rheumatology, Vol. 73, Núm. 2, pp. 336-346

2019

  1. Effectiveness of dabrafenib in the treatment of patients with braf v600-mutated metastatic melanoma in a named patient program

    Melanoma Research, Vol. 29, Núm. 5, pp. 527-532

2018

  1. Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 6, Núm. 4, pp. 1191-1197.e5

2017

  1. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial

    British Journal of Haematology, Vol. 179, Núm. 1, pp. 66-74

2016

  1. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

    The Lancet Haematology, Vol. 3, Núm. 11, pp. e506-e515

  2. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by prior treatment

    Blood, Vol. 127, Núm. 6, pp. 713-721

  3. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria

    Journal of Allergy and Clinical Immunology, Vol. 137, Núm. 2, pp. 474-481

2015

  1. Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma

    Haematologica

  2. Patterns of HER2 gene amplification and response to anti-HER2 therapies

    PLoS ONE, Vol. 10, Núm. 6

2014

  1. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206

2013

  1. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma

    Journal of Clinical Oncology

  2. Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2

    Clinical Breast Cancer, Vol. 13, Núm. 6, pp. 421-432.e8

2008

  1. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells

    British Journal of Haematology, Vol. 141, Núm. 4, pp. 470-482

2005

  1. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: Results of a pilot randomized controlled clinical trial

    Journal of Hepatology, Vol. 43, Núm. 4, pp. 630-636